UK's most commonly prescribed drug cuts dementia risk by 13%, study suggests
A common drug prescribed to help lower cholesterol levels has been found to cut dementia risk.
High cholesterol has long been linked to general poor health, but a recent study published in the Journal of Neurology and Psychiatry revealed it may also increase the risk of dementia.
It found people with lower levels of 'bad cholesterol' in their blood are less likely to develop the memory robbing condition.
The study suggested that cholesterol-lowering statins, the most commonly prescribed drugs in the UK, also offered a boost in protection against dementia.
Cholesterol is a natural fatty substance found in the blood. Low-density lipoproteins (LDL) also known as 'bad cholesterol' can raise the risk of a heart attack or stroke if they are too high.
But exercising and eating healthily can bring these levels down. Drugs called statins, which are given to around 8 million Britons, are also prescribed to those with high cholesterol if lifestyle changes are not enough, helping to prevent cardiovascular event.
However, researchers from Hallym University College of Medicine in South Korea claimed the drug could also protect against dementia.
The scientists analysed data collected by 11 university hospitals which followed adults for 180 days after they got their cholesterol levels tested and observed whether the patients went on to develop dementia in the study period.
Researchers identified 192,213 people with LDL levels less than 1.8 mmol/L and 379,006 patients with LDL levels more than 3.4 mmol/L.
Those with lower LDL levels were 26 per cent less likely to be diagnosed with dementia compared with those who had higher cholesterol levels.
These patients were also 28 per cent less likely to be diagnosed with Alzheimer's disease.
However, if LDL levels dropped below 1.4 mmol/L, participants only had an 18 per cent lower risk of getting dementia or Alzheimer's.
Plus, when LDL levels dipped below 0.8 mmol/L, the protective effect disappeared entirely.
Researchers found the drug statins did boost protection against dementia, even when participants LDL levels were already on the lower side.
For those below 1.8 mmol/L, dementia risk was reduced by 13 per cent and Alzheimer' by 12 per cent in comparison to those who did not take statins.
Dr Julia Dudley, Head of Research at Alzheimer's Research UK says: 'High levels of LDL cholesterol were identified as a risk factor for dementia in last year's Lancet Commission on dementia prevention.'
'The use of statins seemed to offer a protective effect – even in those who already had cholesterol levels within a lower range,' she added.
'However, dementia risk is complex and influenced by many factors. Without a detailed picture of what's going on in the brain we do not know if there is a direct link between lower cholesterol and reduced dementia risk.'
Researchers explained that because it was an observational study, no firm conclusions can be drawn about cause and effect.
The authors concluded: 'Low LDL-C levels (<70 mg/dL (<1.8 mmol/L)) are significantly associated with a reduced risk of dementia, including Alzheimer's disease related dementia, with statin therapy providing additional protective effects.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scottish Sun
an hour ago
- Scottish Sun
The 52p herb that could help prevent Alzheimer's – plus 3 other ways it can benefit your health
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) KNOWN for its strong, pine-like flavour and its use in various dishes, rosemary has a lot more going for it than its scent and taste. The popular herb is starting to gain recognition for its impressive health benefits, especially when it comes to brain health, inflammation and immune function. Sign up for Scottish Sun newsletter Sign up 2 Rosemary has been shown to benefit the brain in several ways Credit: Getty And research published this year suggests it could even help in the fight against Alzheimer's disease - the leading cause of dementia worldwide. Rosemary has previously been linked to memory and mental clarity. In ancient Greece and Rome, students and scholars used rosemary to sharpen concentration and recall, says Dipa Kamdar, senior lecturer in pharmacy practice at Kingston University. Writing for The Conversation, she explains: "Modern science is finding there may have been something in this: in one study, people who inhaled rosemary's scent performed better on memory takes compared to those in an unscented environment." There are several ways rosemary benefits the brain, says Kamdar. Firstly, it stimulates blood circulation, including to the brain, helping deliver more oxygen and nutrients, which may improve mental clarity. It also has calming properties, with some studies suggesting its aroma can reduce anxiety and improve sleep - lower stress means better focus and memory retention. Kamdar adds: "Rosemary contains compounds that interact with the brain's neurotransmitters. One such compound, 1,8-cineole, helps prevent the breakdown of acetylcholine, a brain chemical essential for learning and memory. By preserving acetylcholine, rosemary may help support cognitive performance, especially as we age." And rosemary's antioxidants may also help protect brain cells from damage caused by oxidative stress - which is a major factor in cognitive decline. Kamdar says: " Rosemary is rich in phytochemicals, plant compounds with health-enhancing effects. One of the most powerful is carnosic acid, an antioxidant and anti-inflammatory agent that helps shield brain cells from harm, particularly from the kinds of damage linked to Alzheimer's disease." Five simple tests that could indicate dementia What are rosemary's benefits beyond brain health? 2 Rosemary may aid digestion by stimulating the liver to produce bile Credit: Getty As well as boosting brain health, studies suggest rosemary may aid digestion by stimulating the liver to produce bile, which helps the body digest fat. In a study with mice, it was shown to reduce inflammation in the digestive tract, potentially aiding in the management of IBS and other inflammatory bowel ailments. And rosemary supplementation may also positively impact the gut microbiota, increasing beneficial bacteria like Bifidobacterium and Bacteroidetes, while reducing harmful bacteria like Escherichia coli. Rosemary may also be able to improve immune function. Some studies, particularly in vitro and animal models, suggest that rosemary and its active compounds, like carnosic acid and rosmarinic acid, can influence immune function. Other studies have shown rosemary may promote immune cell activity, such as increasing antibody production or enhancing the activity of immune cells like dendritic cells. Finally, rosemary could prevent certain cancers. Rosemary has been proven to display powerful anticancer efficacy in numerous cancers, including lung, prostate, liver, and breast. Carnosic acid appears to be the plant's primary anticancer component, as it was found in one study to exhibit antiproliferative effects in cancer cells.
STV News
2 hours ago
- STV News
Alzheimer's research suffers 'devastating blow' after new drug rejected by NHS
A woman who has Alzheimer's disease has said the progression of research has suffered a 'devastating blow' after a new drug was rejected for use by NHS Scotland. Donanemab delays the onset of dementia and works by targeting a cause of the disease, rather than just treating its symptoms. But the Scottish Medicines Consortium says there isn't enough evidence to prove how well it works. Recently retired Rynagh has lived an enviable life, growing up in Ireland, moving to the US, and attending New York University. Coming to Scotland, she expected to live out the rest of her life in peaceful retirement. Instead, she found out she had dementia. She's now thrown into finding a cure for Alzheimer's – and says the rejection of this drug is a massive blow. 'What would it take to approve a drug for dementia?', she said. 'Because it seems to be a lost in space for people. There aren't annual check-ups or anything like there are with other diseases. So there's no record of decline, which is unusual when you think about how progress is made with other diseases over time. 'Think about polio, leprosy, and cancer. They were known many years ago, but we don't talk about them because of the needs and the cost. 'And I understand that cost is a factor, but the burden on society, even in comparison to those other diseases, is tremendous. Absolutely. And only tremendous. It's not just the individual, it's the community, it's the family. 'It's the cost to the next generation for what they lose out by having to provide that care and not being able to support their own families, immediate families, in the way that they will.' Donanemab works when antibodies are given by infusion into a vein in the arm – they then bind with amyloids in the brain, a protein that builds up in Alzheimer's patients, and leads to cognitive decline. Those antibodies trigger immune cells, which clear the amyloid – and slow down the alzheimer's process. The Scottish Medicines Consortium rejected donanemab for use on the NHS as it said there wasn't 'enough evidence of how well it works.' Meanwhile manufacturer Lilly claims the decision 'does not consider … the clinical efficacy and cost-effectiveness' of the drug. It's left campaigners worried about the future of dementia research. Henry Simmons, chief executive of Alzheimer Scotland, said: 'The process that all drugs go through at present at the both the NHS in Scotland and England is a reasonable process however, we don't think it is a reasonable way to tackle the issues we face in terms of the size and scale of dementia, and what we are calling for is a rethink on that.' There's hope the SMC will reconsider the drug, but in the meantime, Rynagh hopes people living with dementia don't give up – and that awareness of the illness continues to grow. 'Well, when it comes down to it, it is the public', she added. 'And if the public doesn't have the awareness, they won't push. 'You know, like 66% is that about two thirds of people with dementia are women. Women typically are the caregivers, but then they need the care and it becomes this cycle and it is increasing instead of decreasing. 'And also with the population pyramid is kind of changing as well. We know that that the elderly population is getting bigger and that's it's a disaster that you should be able to see. 'It's not that you're seeing one seventh of the iceberg. We're now coming to the point where it's so far above the water, it should be that you can go around us and go through it and disperse it, but are not even talking about it at the level that we need to be talking about it.' Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
Daily Record
11 hours ago
- Daily Record
'I donated my mum's body to Alzheimer's research instead she was blown to pieces'
Her son said 'she was strapped in a chair, and a detonation took place underneath her' One Arizona man thought he was donating his mother's body to science after her harrowing descent in Alzheimer's - only to discover he had been sent her cremated arm before the rest of her body was strapped to a chair and blown up. Jim Stauffer cared for his mother Doris throughout her illness before she died at 74 in 2013. He decided to donate her brain to science hoping to contribute to a cure for Alzheimer's disease. The family contacted Biological Resource Center, a local company that brokered the donation of human bodies for research. Within the hour, BRC dispatched a driver to collect Doris. Jim signed a form authorizing medical research on his mother's body. Ten days later, Jim received his mother's cremated remains - but it turns out her ashes were made up of a singular arm sawn off from her body. The rest of her corpse had met a violent fate. Doris' brain never was used for Alzheimer's research. Instead, her body became part of an Army experiment to measure damage caused by roadside bombs, reports the Irish Star. Internal BRC and military records show that at least 20 other bodies were also used in the blast experiments without permission of the donors or their relatives, a violation of U.S. Army policy. Jim had also ticked a box specifically banning any kind of experiments on Doris. BRC sold donated bodies like Stauffer's for $5,893 each. Jim said: "She was strapped in a chair, and a detonation took place underneath her to get an idea of what the human body goes through when a vehicle is hit by an IED. There was wording on this paperwork about performing tests that may involve explosions, and we said, 'No'." Army officials involved in the project said they never received the consent forms that donors or their families had signed. Rather, the officials said they relied on assurances from BRC that families had agreed to let the bodies be used in such experiments. BRC, which sold more than 20,000 parts from some 5,000 human bodies over a decade, is no longer in business. Its former owner, Stephen Gore, pleaded guilty to fraud in 2022. In a statement to Reuters, Gore said that he always tried to honor the wishes of donors and sent consent forms when researchers requested them. Jim said of Gore "He didn't care about the families, he didn't care about the people." Jim learned of the fate of his mother's body from a Reuters reporter and "curled his lip in anger and clutched his wife Lisa's arm. "We did right," Lisa reassured him. "They just did not honor our wishes." No federal law regulates body brokers like BRC, and no U.S. government agency monitors what happens to cadavers pledged for use in medical education and research. "It is not illegal to sell a whole body or the parts of a body for research or education," said University of Iowa law professor Sheldon F. Kurtz, who helped modify the Uniform Anatomical Gift Act, which has been adopted by 46 states. Although the act was updated in 2006, Kurtz said, "the issue of whole bodies or body parts for research or education never came up during our discussions." Since then, the body trade has become big business. Only one state, New York, keeps detailed records on the industry. According to the most recent data available, companies that did business in New York shipped at least 100,000 body parts across the country from 2011 to 2014. Reuters obtained the data, which have never been made public, from the state's health department. "I feel foolish," said Jim. "I'm not a trusting person, but, you have no idea this is going on." Military officials said they took BRC's word that permission had been given. Records show at least 20 more bodies were blown up without consent.
